Author Index, Volume 33 (1993)

Abbott KC, 392
Abdallah H, 606
Abernethy DR, 75
Abrams WB, 544
Abu-Elmagd K, 606
Acuff RV, 84
Affrime MB, 136
Ajami A, 246
Akopov SE, 1048
Al-Abdely H, 450
Almirez RG, 707
Ambrosioni E, 40
Ameer B, 1013
Andersson S, 703
Antony KK, 458
Arnold RJG, 989
Ayass M, 811

Bachmann K, 861, 1219
Bakris G, 392
Balfour DJK, 400
Bannwarth B, 475
Barbhaiya RH, 568, 912, 1104
Barr WH, 1207
Barth J, 115
Bass AS, 747
Batenhorst RL, 1116
Bauer C, 1011
Bauer JH, 348
Bell RD, 427
Benn H-P, 330
Berger BM, 381, 1207
Berthold CW, 944
Beyer KH Jr, 554, 823
Bhargava VO, 354, 439
Biugi GL, 1011
Bjornsson TD, 581
Blum RA, 1225
Boddy AW, 381, 1207
Borer JS, 1039
Borghi C, 40
Boschi S, 40
Bouchama A, 450
Bourgeois J, 832
Bournazos C, 470
Bowen JP, 1149
Bowles SK, 727
Brady EM, 418
Braegelmann F, 1039
Bransome ED Jr, 1147
Branzi A, 40
Brater DC, 912
Brawer MK, 866
Brent J, 497
Brooks CD, 816
Browne TR, 89, 246
Bryant NR, 412
Buch AB, 1104
Bungo MW, 535
Burford HJ, 400
Buschmann M, 330
Busto, U, 124

Caccia S, 845
Calderwood JA, 22
Calkins DS, 1092
Camara DS, 805
Campagna KD, 527
Campia U, 433
Cantelli-Forti G, 1011
Cantilena LR, 1201
Caputo S, 226
Capuzzi DM, 366
Cardillo C, 433
Cardozo L, 727
Carruthers SG, 260
Castañeda-Hernández G, 140
Cathcart KS, 175, 182
Cavanah SFW, 253
Cavanaugh JH, 719
Celle G, 70
Chambers CE, 823
Charifson PS, 1149
Charles JB, 535, 1071
Charman WN, 381, 1207
Chow MSS, 623
Chu S-y, 480
Chu SY, 719
Clark CR, 527
Cleophas TJM, 799
Clevenger B, 1165
Coen P, 169
Cohen J, 272
Colborn DC, 373
Confalonieri S, 845
Conner DP, 707
Conrad J, 463
Conroy JA, 581
Corboy JE, 703
Corder CN, 35
Cretkovic A, 752
Cronenberger CL, 657
Croughwell ND, 360
Cubeddu LX, 691
Cummins VPS, 63
Cunha BA, 923
Currie WJC, 100
Cusson JR, 732
Cutela P, 70
Cutler NR, 463

Daigneault EA, 84
Dana S, 1165
Dangoumau J, 475
Das G, 296
Davoudi H, 89
Dawood MY, 1116
De Felice F, 433
Dean RT, 1039
Deaton RL, 719
Decourt JPh, 480
Degen C, 433
Demers LM, 823
Demotes-Mainard F, 475
Derendorf H, 115, 811
Desager JP, 929
Desche P, 146
Dews IM, 146
Diamandis PH, 535
Dionne RA, 944
Diskin CJ, 527
Dixon R, 955
Djordjevic-Denic G, 342
Dougherty CL, 89
Doyle H, 599
du Souich P, 732
Dussack LG, 535
Dye D, 161

Eason CN, 719
Eberhardt RT, 1023
Ebihara A, 222, 640, 738, 756, 1188, 1192, 1233
Echizen H, 324, 979
Edgar B, 732
Edwards DJ, 727
Ehrenpreis S, 279, 670
Einarson T, 405
Elberfeld JM, 458
Eldadah MK, 29
Eldon MA, 53
Elliot WJ, 549
El-Yazigi A, 450, 522
Euler AR, 79
Evans BA, 89
Evans JE, 89

Farmen RH, 631
Feig PU, 418
Feigenbaum A, 405
Feinberg JA, 544
Feldmann R, 588
Ferguson RK, 544
Ferrari P, 866
Ferslew KE, 84
Fisher JR, 623
Fleishaker JC, 175, 182, 463
Flores-Murrieta FJ, 140
Flynn K, 453
Folli G, 433
Foss JF, 747
Fourtillan JB, 480
Fox PC, 1149
Francom SF, 816
Frishman W, 46
Frishman WH, 612, 752, 1023
Froeschke MO, 150
Fruncillo RJ, 581
Fujihara H, 230
Fujii I, 130, 851
Fujimura A, 222, 640, 738, 756, 1188, 1192, 1233
Fujitaki J, 955
Fullerton T, 1225
Fung J, 599, 606

Gaber M, 513
Gabrielian ES, 1048
Gelarden RT, 554
Ghirlanda G, 226
Giannini AJ, 1139
Gibaldi M, 488
Giesing DH, 354, 439
Gilliland S, 918
Girault J, 480
Glazer PA, 109
Gleeson MAG, 1165
Goldberg LI, 747
Gomez H, 497
Good WR, 366
Goodfriend TL, 971
Goodman DK, 360
Gorsline J, 161, 169, 644
Graham K, 405
Granneman GR, 480
Greco AV, 226
Green JA, 549
Greenblat DJ, 75
Greenblatt DJ, 650
Gregoire S, 967
Griffith RK, 657
Gross S, 811
Guay DRP, 918
Guido M, 845
Guiso G, 845
Guler H-P, 366
Gupta SK, 161, 169

Hakusui H, 57
Hardoff R, 1039
Hardy JG, 712
Harvengt C, 929
Harvey WJ, 712
Hasegawa J, 444, 1086
Hashimoto S, 57
Hatfield NZ, 373
Hegland J, 967
Heiman M, 46
Hendry LB, 1173
Herrold EM, 1039
Heykants J, 1214
Higashi A, 1238
Hirschman SZ, 470
Hisatome I, 444
Hitzenberger G, 936
Hochhaus G, 115
Hoffmann IS, 691
Hoke JF, 458
Holland SD, 581
Honig PK, 1201

Hoon TJ, 1116
Hopkinson JM, 703
Horky K, 866
Horsmans Y, 929
Horst HM, 562
Houston MC, 264
Hoyo-Vadillo C, 140
Hsu PH, 762
Huang ML, 1214
Hulhoven R, 929
Hull R, 1201
Hunninghake DB, 574, 967
Hyoki K, 741

Iasalo E, 959
Imagawa M, 154
Inotsume N, 1238
Ishizaki T, 324, 979

Jaber LA, 239
Jacobs JR, 360
Jacobson JM, 253
Jain AB, 606
Jamali F, 1052
Jauregui L, 861, 1219
Jähnchen E, 330, 513
John VA, 366
Johnson J, 904
Johnson JM, 22, 1015
Johnston A, 513, 936
Jovovic D, 342
Jusko WJ, 805

Kacew S, 213
Kaila T, 959
Kaitin KI, 412
Kamagai Y, 1192
Kamakura H, 1086
Kanamaru M, 57, 1122
Kaneda T, 444
Kang PM, 1023
Kaniecki DJ, 989
Kaplan MM, 75
Karl KJ, 816
Kaunitz JD, 63
Kawamuro Y, 741
Kedar A, 811
Keefe DL, 1060, 1133
Kendrick ZV, 136
Kentera D, 342
Kevak RM, 1023
Khan-Dawood FS, 1116
Khosla S, 279, 670
Kisicki J, 955
Klassen D, 971
Kluger J, 623
Knaus V, 348
Knupp CA, 568, 912
Knutson DW, 554
Ko Y, 230
Kodama H, 851
Kodama Y, 130, 851
Koelle EU, 936
Kohl RL, 1092
Kong AN, 805
Kontoyianni M, 1149
Koren G, 405
Kotake H, 444
Kotegawa T, 1188, 1192
Kovarik JM, 513, 936
Kozlik-Feldmann R, 588
Kramer H-H, 588
Kres J, 89
Krieg M, 115
Kriegman AG, 418
Kuchel O, 866
Kumagai Y, 222, 1188
Kuranari M, 851
Kyncl JJ, 866

Lacourcière Y, 832
Lalka D, 657
Lanctôt KL, 124
Landau A, 752
Larochelle P, 732
Lasagna L, 412
Laskin OL, 636
Lasseter KC, 636
Lathers CM, 535, 837, 1071
Lau A, 348
Lees AM, 1039
Lees RS, 1039
Leibowitz D, 508
Lembke JM, 335
Lewis NJW, 239
Lewis RC, 373
Li RC, 373, 933
Lieberman R, 596, 599
Lippa S, 226
Lister-James J, 1039
Littarru GP, 226
Lowenthal DT, 136
Lucca U, 845
Luderer JR, 150
Ludwig EA, 805

Macarios M, 712
Mackenthun AV, 719
MacKichan JJ, 790
Magnani B, 40
Mandal AK, 342, 427
Manto A, 226
Markert RJ, 427
Marshall GB, 712
Mashiba H, 444
Matsubayashi K, 57
Matsuda I, 1238
May S, 418
McCauley J, 599
McConathy W, 35
McCrea JB, 581
McDonnell DP, 1165
McEntegart C, 89
McIntyre T, 253
McMichael J, 599
McMillian CL, 527
Mehta P, 811
Mela GS, 70
Melandri G, 40
Mele R, 70
Mellies MJ, 574
Mendelson MH, 470
Merdjan H, 936
Metzler CM, 150
Meyers BR, 470
Miceli JJ, 89
Mihara M, 1086
Milbrath R, 568
Miller AB, 1149
Miller LG, 703
Millora E, 707
Mills R, 79
Minami R, 1238
Minoura S, 979
Minuk GY, 949
Mishler D, 63
Misiak PM, 53
Mitchell J, 46
Miyamoto G, 230
Mizuno A, 57, 1122
Mlynarek M, 562
Mohammed SS, 811
Morgan JM, 366
Morishita N, 1086
Morlat P, 475
Motil KJ, 703
Möllmann C, 115
Möllmann H, 115
Mueller EA, 513, 936
Mukai C, 535
Mulvagh SL, 535
Murphy MB, 549

Nagami GT, 63
Nagashima S, 1122
Nakano M, 1238
Nakano S, 154
Nakashima H, 154, 1188, 1192
Nakashima M, 57, 1122
Nara AR, 549
Narang PK, 373, 933
Neale AV, 239
Netz H, 588
Newth CJL, 29
Nierenberg DW, 311
Nishikawa Y, 741
Nix D, 707
Nordbrock EE, 439

Odomi M, 230
Offermanns J, 124
Ohashi K, 222, 738, 756, 1188, 1192, 1233
Ohashi K-i, 640
Ohnishi A, 230, 1086
Okada K, 230
Okazaki O, 57
Okerholm RA, 169, 458
Oradei A, 226
Osada Y, 57
Osaki S, 444

Pagliaro AM, 676
Pagliaro LA, 676
Palma-Aguirre JA, 140
Panacek EA, 549
Paolini M, 1011
Parma E, 845
Passananti GT, 823
Patterson PM, 636
Penner SB, 1110
Peters GR, 175, 182
Peterson CA, 971
Peterson EL, 562
Peterson J, 335
Phillips S, 497
Pichotta PJ, 480
Piepho RW, 2
Pierri MK, 1060
Pilmer BL, 549
Piraino AJ, 366
Piscitelli SC, 698
Pittman KA, 631
Poirier L, 832
Prather RD, 169, 644

Qadri SMH, 923
Quon C, 89

Rabkin SW, 286
Ragnaud JM, 475
Ram CVS, 866
Ramos J, 1116
Ratcliffe A, 109
Ravis WR, 527
Reams GP, 348
Reeves RA, 727
Reinhardt D, 588
Relue J, 912
Repsher LH, 856
Reschke MF, 1092
Resplandy G, 146
Reves JG, 360
Reyes G, 29
Richelson E, 1092
Riddle JM, 535
Rieder MJ, 316
Robert S, 562
Robinson J, 146
Rodvold K, 918
Rodvold KA, 698
Rogge MC, 381, 1207
Roistacher N, 1060
Rolf CN, 161, 644
Rosenthal J, 866
Rosenwasser MP, 109
Rossi DT, 373, 933
Rotmensch HH, 544
Rotschafer J, 918
Ruiz I, 124
Rushing DA, 698
Russell AS, 1052
Rutan GH, 418
Rutherford W, 549

Saelens DA, 335
Saima S, 324
Sakamoto K, 222, 738, 1233
Saldin H, 923

Sandoval T, 955
Sandoz GR, 1092
Santiso-Mere D, 1165
Saotome T, 979
Saris SD, 366
Sato T, 979
Savarino V, 70
Schnur D, 1149
Schraeder PL, 837
Schuna AA, 971
Schwartz PH, 29
Sciacca MA, 631
Seaman J, 366
Sedman AJ, 53
Seidehamel RJ, 1104
Seiler K-U, 330
Shah AK, 354, 439
Shah VP, 707
Shamblen EC, 636
Shields BJ, 790
Shiga T, 640, 756, 1188, 1192, 1233
Shigeta M, 741
Shimizu M, 741
Shingo S, 581, 636
Shroff G, 279, 670
Sica DA, 1225
Sides G, 861
Sieck JO, 450
Simons FER, 949
Simons KJ, 949
Sirgo MA, 79
Sisson TA, 463
Skeith KJ, 1052
Slaughter RL, 239
Smith JE, 1201
Smyth DD, 1110
Solomon GD, 200
Somberg J, 279, 670
Somberg JC, 1, 99, 199, 259, 295, 391, 487, 587, 675, 779, 903
Sostrin MB, 631
Spagnoli A, 845
Sparrow RA, 712
Spector R, 581
Sramek JJ, 463
Stanko CK, 1110
Stanton PE Jr, 84
Starzl TE, 599, 606
Steed KP, 712
Steenwyk RC, 182
Stein EA, 574
Stephen A, 1214
Stephens JD, 146
Stevenson IH, 400
Stewart EL, 1149
Stojanov M, 342
Studer JA, 2
Sudo T, 222, 738, 1233
Sudo Y, 1238
Sudoh T, 640
Sugiyama A, 1122
Sullivan TJ, 861, 1219
Sunaga K-i, 640
Susic D, 342
Sussman NM, 458
Szabo GK, 89, 246
Szathmary S, 330

Takeyama M, 130, 851
Tanaka T, 1086
Tanner LA, 904, 1015
Tateishi T, 154, 222, 640, 738, 756, 1233
Tavella M, 35
Tay LK, 631
Taylor AM, 967
Tejero C, 470
Terakawa M, 1122
Teraoka I, 130
Terashi K, 979
Tettamanti M, 845
Tewksbury DA, 698
Thibault G, 732
Tiraboschi P, 845
Tisdale JE, 623
Todo S, 606
Tomono Y, 1086
Toothaker RD, 53
Trenk D, 330
Tsutsumi K, 130, 154
Tu TG, 644
Tumer N, 837
Tunn S, 115
Tzukerman MT, 1165

Uccioli L, 226
Uematsu T, 57, 1122
Ueno Y, 923
Usui M, 741

Van Dyke C, 1149
Van Harken DR, 1104
Van Peer A, 1214
Vance-Bryan K, 918
Vandenburg MJ, 146
Vary JE, 554
Venkataramanan R, 606
Veroff AE, 463
Vesell ES, 554, 823
Vinçon G, 475
Vlasses PH, 544
von Moltke LL, 75
Wagner D, 246
Wahab FA, 522
Walker S, 79
Ward RM, 780
Ward TD, 554
Warty V, 606
Watanabe M, 444
Watson A, 1134
Watson WTA, 949
Weidmann P, 866
Weir SJ, 354, 439
White WD, 360
Wicht H, 588
Wilding IR, 712
Wilkinson P, 470
Wilson DS, 719
Wilson JT, 210
Winchell GA, 967
Woestenborghs R, 1214
Wolf DL, 150
Woolley TW, 84
Woo-Ming RB, 14
Wortham DC, 1201

Yamazaki K, 1086
Yoshimoto K, 324
Young DY, 971
Yuh L, 458
Yusuf A, 450

Zamani K, 707, 1201
Zanchetti A, 866
Zanzonico P, 1039
Zarowitz BJ, 562
Zawada ET Jr, 335
Zazgornik J, 1214
Zentilin P, 70
Zsigmond EK, 453

Subject Index, Volume 33 (1993)

Acadesine
disposition and metabolism, 955
Acebutolol
selectivity in healthy volunteers estimated by extent that drugs occupy β_2-receptors in circulating plasma, 959
ACE-Inhibitors
partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with, 40
Acetaminophen
physiologically-based pharmacokinetic model of acetaminophen for application in analysis of space flight data, A770
Adenylate cyclase
myocardial β-adrenoreceptor subtype distribution and coupling with adenylate cyclase in children with congenital heart disease, 588
Adinazolam
psychomotor and memory effects of two formulations assessed by computerized neuropsychological test battery, 463
Adrenergic Receptor Blockers
mechanisms of action on lipids during antihypertensive drug treatment, 286
Adriamycin
prevention of adriamycin induced cardiac toxicity with carnitine, A998
Adverse Drug Effects
in children, 316
drugs and chemicals in breast milk, effects on nursing infants, 213
low side effects in oral treatment with budesonide in healthy volunteers, A999
Air Flight. *See also* **Space Flight**
autogenic feedback training improvement of pilot performance during high stress conditions, A773
Alpha Blockade. *See also* **Antihypertensive Agents**
adrenergic receptor blocker mechanisms of action on lipids during antihypertensive drug treatment, 286
alpha$_1$-adrenergic blocking agents in geriatric patients, 2
alpha$_1$-receptor blockade with terazosin, 866
effectiveness in risk reduction, 264
place in antihypertensive therapy, 260
racial differences in α-adrenergic and prostaglandin receptors, A1009
risk factors not addressed in antihypertensive therapy based solely on blood pressure control, 279
selective alpha-1 adrenoreceptor blockade and renal sodium handling in humans, 1110
symposium on, 259
terazosin long-term efficacy and safety, 272
Alpha-Tocopherol
pharmacokinetics and bioavailability of RRR and all racemic stereoisomers in humans after single oral administration, 84
Alprazolam
pharmacokinetic interaction between buspirone and, at steady state, 1104
Alzheimer's Disease
pharmacokinetics of E2020 in healthy young and elderly subjects, 1086
Amiodarone
risk factors for toxicity, A1006
Amphetamine
facilitation of adaptation and acute tolerance to stressful sensory input by, 1092
Analgesics
codeine disposition in sickle cell patients compared with healthy volunteers, 811
effects of concomitantly administered cimetidine or ranitidine on pharmacokinetics of ritanserin, 330
hemofiltrability of nizatidine and its metabolites in patients with renal failure, 324
H_1-receptor and H_2-receptor antagonists for acute postoperative pain, 944
ibuprofen suspension in children with pain, A1002
naproxen and interleukin-1 effects on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage *in vitro*, 109
pharmacokinetics and dialyzability of sulindac and metabolites in end-stage renal failure, 527
pharmacokinetics of cyclosporine and steady-state aspirin during coadministration, 513
Androgenic Steroids
use at major medical center, 253
Anesthesia
ultra-long duration local anesthesia with lecithin-coated tetracaine microcrystals, A772
Angina Pectoris
anti-anginal and anti-ischemic efficacy of immediate release nisoldipine in, A999
Angiotensin II
in cardiovascular pharmacotherapy, 1023
reversible effect on baroreceptor neuron calcium currents, A774
slow IV infusion of E-3174 metabolite of losartan in hypertension, A1003
Anthracycline
echocardiographic characteristics of anthracycline induced cardiomyopathy, A1004
Antiarrhythmia Agents
efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs, 623
risk factors for amiodarone toxicity, A1006
Antibiotics
kinetics of effect on locomotory responses of polymorphonuclear leukocytes, A1009
phase I study of DQ-2556, 57
single- and multiple-dose pharmacokinetics of clarithromycin, 719
Antiemetics
dose-related antagonism of emetic effect of morphine by methylnaltrexone in dogs, 747
participation of serotonin on early and delayed emesis induced by cisplatinum-based chemotherapy, 691
Antihistamines
effect of itraconazole on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201
Antihypertensive Agents. *See also* **Alpha Blockade**
adrenergic receptor blocker mechanisms of action on lipids during treatment with, 286
alpha$_1$-adrenergic blocking agents in geriatric patients, 2
alpha blockers in, 260
alpha$_1$-receptor blockade with terazosin, 866
blood pressure assessment during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide, 971
blood pressure control, hematocrit level, and renal function in treated essential hypertension, 427
chronopharmacokinetic profiles of propranolol and atenolol in hypertensive subjects, 756
combination drug therapy with calcium-channel blockers in systemic hypertension, 752
comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring, 418
enalapril effects in hypertensive patients with proteinuria and impaired glucose metabolism, A771
enalapril versus nifedipine in diabetic patients with hypertension and proteinuria, A772
extended-release formulation of diltiazem HCl for treatment of mild-to-moderate hypertension, 612
fenoldopam mesylate versus sodium nitroprusside in acute management of severe systemic hypertension, 549
labetalol during third trimester of pregnancy, 979
lisinopril influence on urinary electrolyte excretion after furosemide in healthy subjects, 640
once-daily trandolapril compared with twice-daily formulation in mild to moderate essential hypertension, 832
pyrazinoylguanidine effects on glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus, 823
pyrazinoylguanidine versus hydrochlorothiazide in patients with renal insufficiency, 554
renal effects of, 392
renin-angiotensin-aldosterone system and prostaglandin role in antihypertensive effect of heparin, 342
risk factors not addressed in antihypertensive therapy based solely on blood pressure control, 279
slow IV infusion of E-3174 metabolite of losartan, A1003
spirapril effects on renal hypertension in patients with essential hypertension, 348
terazosin and enalapril effects on laboratory stress testing blood pressure in essential hypertension, 433
transdermal clonidine pharmacokinetics and pharmacodynamics, 1192
influence of application site on, 1188
verapamil in hypertensive rats on high-calcium diet, 335
Anti-Infective Agents
aztreonam pharmacokinetics in healthy elderly and young adult volunteers, 470
didanosine and ketoconazole pharmacokinetics after coadministration in patients seropositive for human immunodeficiency virus, 912
effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics, 480
effect of time of food administration on bioavailability of didanosine from chewable tablet formulation, 568
gentamicin pharmacokinetics determination by bioelectrical impedance in critically ill adults, 562
oral cimetidine or ranitidine effects on pharmacokinetics of intravenous enoxacin, 53
pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis, 475
phase I study of DQ-2556, 57
single-dose pharmacokinetics of cetirizine in chronic liver disease, 929

vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster, 918
in vitro activity of Ro 23-9424, 923
Anti-Inflammatory Agents
blood pressure assessment during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide, 971
cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949
effects of concomitantly administered cimetidine or ranitidine on pharmacokinetics of ritanserin, 330
enhancement of pain control in sickle cell vasoocclusive crisis by intravenous keterolac, A1009
hemofiltrability of nizatidine and its metabolites in patients with renal failure, 324
ketoprofen pharmacokinetics in elderly, rheumatic disease, renal function, and dose and, 1052
methylprednisolone hemisuccinate and methylprednisolone pharmacokinetics in chronic liver disease, 805
naproxen and interleukin-1 effects on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage *in vitro*, 109
NSAID-induced small intestinal permeability, rat as model for human, A998
oral methylprednisolone acetate for seasonal rhinitis, 816
pharmacokinetics and dialyzability of sulindac and metabolites in end-stage renal failure, 527
pharmacokinetics of cyclosporine and steady-state aspirin during coadministration, 513
receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids, 115
renal protective effect of misoprostol in elderly, osteoarthritis patients at risk for NSAID-induced renal dysfunction, 1225
Anti-Neoplatelet Agents
doxorubicin disposition on repeated dosing, 698
participation of serotonin on early and delayed emesis induced by cisplatinum-based chemotherapy, 691
Antiplatelet Drugs
relationship between degradation of prostacyclin in blood and antiplatelet drug effects in, 1048
Antipyrine
kinetics in patients with primary biliary cirrhosis, 75
lack of effect of finasteride on oxidative metabolism of, 967
Arginine Vasopressin
etiological significance in motion sickness, A767
Artificial Intelligence
computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders, 599
FK506 pharmacokinetics in liver transplant recipients after continuous intravenous infusion, 606
pharmacoeconomics and, 596
5-ASA
localization of drug release sites from oral sustained-release formulation in gastrointestinal tract using gamma scintigraphy, 712
Aspirin
pharmacokinetics of cyclosporine and steady-state aspirin during coadministration, 513
Atenolol
chronopharmacokinetic profile in hypertensive subjects, 756
comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring, 418
impaired elimination in nephropathic patient with self-medication overdose, 450
selectivity in healthy volunteers estimated by extent that drugs occupy β_2-receptors in circulating plasma, 959
Atherosclerosis
external imaging in rabbits using ^{123}I-labeled synthetic peptide fragment, 1039
relationship between degradation of prostacyclin in blood and antiplatelet drug effects in, 1048
Autoimmune Disorders
computer dosing system for individualizing FK506 therapy in, 599
Azathioprine
pharmacokinetics after repeated oral and single intravenous administration, 522

Baroreceptor Reflex
reversible effect of angiotensin II on baroreceptor neuron calcium currents, A774
Benzodiazepines
comparison of use in Canada and Chile, 124
Beta Blocking Drugs
beta-adrenergic blocking properties of S- and R-timolol in humans, 544
effects of IV methylscopolamine in young men on steady-state β-blocker treatment, A1003
sotalol, 508
Bioavailability. See **Pharmacokinetics**
Blood
correlation between skin and platelet activity of minoxidil sulfotransferase, A1005
triboluminescence in phagocytosis, A774
Blood Pressure. *See also* **Antihypertensive Agents; Hypotension**
simultaneous transcranial Doppler and arterial blood pressure response to lower body negative pressure, A770
Book Reviews
α-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, 191
β-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, 191
Advances in Drug Therapy of Gastroesophageal Reflux Disease, 191
Atrial Fibrillation: Mechanisms and Management, 192
Bacterial Meningitis, 192
The Biology of Nicotine, 387
Cardiovascular Drugs and the Management of Heart Disease, 2nd Edition, 387
Cardiovascular Toxicity, 775
Clinical Immunotoxicity, 387
Immunological and Pharmacological Aspects of Atopic and Contact Eczema, 191
Kidney, Proteins and Drubs, 387
Ophthalmic Toxicology, 775
Pain Versus Man (Advances in Pain Research and Therapy, Vol. 20), 387
Patient Recruitment in Clinical trials, 775
Toxicology of the Kidney, 775
USAN and the USP Dictionary of Drug Names, 192
Breast Milk
adverse effects of drugs and chemicals in, on nursing infants, 213
disposition of olsalazine and metabolites in, 703
Bromocriptine
reversal of cocaine abstinence-related dysphoria by, A1006
Bronchitis
iodinated glycerol for treatment of stable chronic bronchitis, 856
lomefloxacin versus cefuroxime axetil in acute bacterial exacerbation of, A1007
Budesonide
low side effects in oral treatment with, in healthy volunteers, A999
pharmacodynamics after rectal application in healthy volunteers, A1000
Bunazosin
interaction with rifampicin, A998
Buspirone
pharmacokinetic interaction between alprazolam and, at steady state, 1104

Calcium-Channel Blockers
combination drug therapy with, in systemic hypertension, 752
nisoldipine, 46
Captopril
pharmacokinetic interaction with moricizine in healthy volunteers, A1005
Carbamazepine
in vivo determinations of carbamazepine and carbamazepine-10,11-epoxidebindingparameters to serum proteins in monotherapy, 851
Cardiomyopathy
echocardiographic characteristics of anthracycline induced cardiomyopathy, A1004
Cardiovascular System
acadesine disposition and metabolism, 955
acebutolol, atenolol, and metoprolol selectivity in healthy volunteers estimated by extent that drugs occupy β_2-receptors in circulating plasma, 959
alpha$_1$-adrenergic blocking agents in geriatric patients, 2
angiotensin II receptor blockade, 1023
anti-anginal and anti-ischemic efficacy of immediate release nisoldipine in chronic stable angina pectoris, A999
autonomic orthostatic hypotension in patients and bedrest subjects, A770
beta-adrenergic blocking properties of S- and R-timolol in humans, 544
beta-methyldigoxin pharmacokinetics in subjects with normal and impaired renal function, 154
cardiovascular control during head-up tilt following 28 days head-down bedrest, A769
clentiazem pharmacokinetics after intravenous and oral administration in healthy subjects, 354
clinical cardiotoxicity of 5-fluorouracil, 1060
codeine effects on ventricular fibrillation threshold, A1006
continuous intravenous dosing with ciprostene using portable pump in ambulatory patients, 150
digoxin pharmacokinetics and perindopril in heart failure, 146
diltiazem pretreatment periods, effect on nifedipine kinetics, 222
echocardiograms during six hours of bedrest at head-down and head-up tilt and during space flight, 535
echocardiographic characteristics of anthracycline induced cardiomyopathy, A1004
effect of anti-G suit inflation on cardiac volumes determined by two-dimensional echocardiography during +Gz acceleration, A768
effect of itraconazole on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201
effect of magnesium sulfate on action potential duration and cardiac arrhythmias, A1001
effect of oral moricizine and epinephrine on defibrillation thresholds, A1008
effects of hypoxia on use-dependent inhibition of conduction velocity induced by cibenzoline in guinea pig ventricular myocardium, 444
efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs, 623
ethanol effects on metabolic responses to treadmill running in well-trained men, 136

ethnic differences on effect of heart failure on clearance of theophylline, A1004
extended-release formulation of diltiazem HCl for treatment of mild-to-moderate hypertension, 612
gemfibrozil effects on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia, 35
hypothermia and sampling site effects on blood esmolol concentrations, 360
impaired elimination of atenolol in nephropathic patient with self-medication overdose, 450
isoproterenol pharmacokinetics in critically ill pediatric patients, 29
lower body negative pressure to assess changes in orthostatic heart rate response during 17 weeks of bedrest, A769
lower body negative pressure to counter symptoms of orthostatic intolerance in patients, bed rest subjects, and astronauts, 1071
myocardial β-adrenoreceptor subtype distribution and coupling with adenylate cyclase in children with congenital heart disease, 588
neuropeptide-Y protection of ventricle from arrhythmogenic actions of norepinephrine without reducing contractility, A1009
nifedipine effects on pharmacokinetics and dynamics of diltiazem in normal volunteers, 738
nifedipine pharmacokinetics in different populations, 140
nisoldipine, 46
OPC-21268 pharmacokinetics, safety, and pharmacologic effects in humans, 230
partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors, 40
pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine, 727
plasma CoQ10-lowering effect by HMG-CoA reductase inhibitor, 226
prevention of adriamycin induced cardiac toxicity with carnitine, A998
renal effects of nonhypotensive IV dose of felodipine, 732
responses to acute and repetitive hyper- and hypogravity produced by parabolic flight, A769
risk factors for amiodarone toxicity, A1006
simultaneous transcranial Doppler and arterial blood pressure response to lower body negative pressure, A770
single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers, 439
syncope and, A770

Carnitine
prevention of adriamycin induced cardiac toxicity with, A998

Ceftazidime
pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis, 475

Cefuroxime axetil
lomefloxacin versus, in acute bacterial exacerbation of chronic bronchitis, A1007

Central Nervous System
effects of motion sickness on, A768

Central Nervous System Agents
benzodiazepine use in Canada and Chile, 124
dose-related antagonism of emetic effect of morphine by methylnaltrexone in dogs, 747
effect of food on bioavailability of gepirone in humans, 631
effects of unbound clearance on binding parameters of valproic acid to serum proteins, 130
facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine, 1092
horizontal component of electro-oculogram as parameter of arousal in dementia under pharmacotherapy, 741
pharmacokinetic interaction between buspirone and alprazolam at steady state, 1104
pharmacokinetics of E2020 in healthy young and elderly subjects, 1086
phenobarbital effects on autonomic function and epileptogenic activity induced by hippocampal injection of penicillin in cats, 837
psychomotor and memory effects of adinazolam formulations assessed by computerized neuropsychological test battery, 463
secobarbital and morphine effects on arterial blood gases in healthy human volunteers, 453
single-dose safety and pharmacokinetics of CL 275,838 in healthy volunteers, 845
vigabatrin pharmacokinetics following single and multiple oral doses in normal volunteers, 458
in vivo determinations of carbamazepine and carbamazepine-10,11-epoxide binding parameters to serum proteins in monotherapy, 851

Cephalosporins
phase I study of DQ-2556, 57

Cetirizine
pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949
single-dose pharmacokinetics in chronic liver disease, 929

Children
abusable psychotropic use among North American youth, 676
adverse effects of drugs and chemicals in breast milk on nursing infants, 213
disposition of olsalazine and metabolites in breast milk, 703
drug therapy of the fetus, 780
etoposide pharmacokinetics in children and infants with short-term and continuous infusion, A1007
evaluation and counseling of teratogenic risk, 405
gastrointestinal decontamination in acute toxin ingestion, 497
ibuprofen suspension in children with pain, A1002
immunopharmacology and adverse drug reactions in, 316
isoproterenol pharmacokinetics in critically ill patients, 29
myocardial β-adrenoreceptor subtype distribution and coupling with adenylate cyclase in congenital heart disease, 588
pediatric pharmacology, 210

Chronic Obstructive Pulmonary Disease
theophylline steady-state pharmacokinetics in COPD patients treated with dirithromycin, 861

Chronopharmacology, A772

Cibenzoline
effects of hypoxia on use-dependent inhibition of conduction velocity induced in guinea pig ventricular myocardium by, 444

Cimetidine
effects on pharmacokinetics of ritanserin, 330
effects on theophylline oxidative metabolism, 1233
oral, effects on pharmacokinetics of intravenous enoxacin, 53

Ciprostene
continuous intravenous dosing using portable pump in ambulatory patients, 150

Cirrhosis
antipyrine kinetics in patients with primary biliary cirrhosis, 75
cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949

Cisapride
effect on esophageal exposure to acid through acceleration of gastric emptying, A1002

Cisplatinum
participation of serotonin on early and delayed emesis induced by cisplatinum-based chemotherapy, 691

CL 275,838
single-dose safety and pharmacokinetics in healthy volunteers, 845

Clarithromycin
effect of moderate or severe hepatic impairment on pharmacokinetics of, 480
single- and multiple-dose pharmacokinetics of, 719

Clentiazem
pharmacokinetics after intravenous and oral administration in healthy subjects, 354
single and multiple oral dose pharmacokinetics in normal volunteers, 439

Clinical Pharmacology
legal curriculum for clinical pharmacologists, 22
teaching, 311

Clonidine
transdermal, pharmacokinetics and pharmacodynamics in healthy subjects, 1192
influence of application site on, 1188

Clozapine Glucuronide
in patient urine after using GC-MS, A1000

Cocaine
cocaine abuse in North America, 296

Codeine
disposition in sickle cell patients compared with healthy volunteers, 811
effects on ventricular fibrillation threshold, A1006
multiple-dose evaluation of pharmacokinetics of codeine sulfate sustained-release tablets, A1006

CoQ10
lowering by HMG-CoA reductase inhibitor, 226

Corticosteroids
receptor-based pharmacokinetic-pharmacodynamic analysis of, 115
reflectance spectrophotometry in human corticosteroid skin blanching assay, 707

Cyanide
intramuscular antidotes for cyanide poisoning, A997

Cyclosporine
pharmacokinetics during coadministration with multiple-dose diclofenac, 936
pharmacokinetics of cyclosporine and steady-state aspirin during coadministration, 513

Danazol
absorption after administration to different sites of gastrointestinal tract and relationship to single-and double-peak phenomena in plasma profiles, 1207
effect of food and monoglyceride emulsion formulation on bioavailability of, 381

Dementia
horizontal component of electro-oculogram as parameter of arousal in dementia under pharmacotherapy, 741

Diabetes Mellitus
effect of stress on glycemic control in type II diabetes during glyburide and glipizide therapy, 239
enalapril versus nifedipine in diabetic patients with hypertension and proteinuria, A772
pyrazinoylguanidine effects on glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus, 823

Dialysis
pharmacokinetics and dialyzability of sulindac and metabolites in end-stage renal failure, 527
pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis, 475

Diclofenac
pharmacokinetics of multiple-dose diclofenac during coadministration with cyclosporine, 936
Didanosine
effect of time of food administration on bioavailability from chewable tablet formulation, 568
pharmacokinetics after coadministration with ketoconazole in patients seropositive for human immunodeficiency virus, 912
Digoxin
beta-methyldigoxin pharmacokinetics in subjects with normal and impaired renal function, 154
pharmacokinetics in heart failure, 146
Diltiazem
effects on theophylline oxidative metabolism, 1233
extended-release formulation of diltiazem HCl for treatment of mild-to-moderate hypertension, 612
nifedipine effects on pharmacokinetics and dynamics of, in normal volunteers, 738
pharmacokinetics and pharmacodynamics of twice-a-day formulations, A997
pretreatment with, effect on nifedipine kinetics, 222
Dirithromycin
theophylline steady-state pharmacokinetics in COPD patients treated with, 861
Diuretics
blood pressure assessment during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide, 971
lisinopril influence on urinary electrolyte excretion after furosemide in healthy subjects, 640
pyrazinoylguanidine versus hydrochlorothiazide in patients with renal insufficiency, 554
Doxepin
facilitation of adaptation and acute tolerance to stressful sensory input by, 1092
Doxorubicin
disposition on repeated dosing, 698
DQ-2556
phase I study of, 57
Drug Abuse
abusable psychotropic use among North American youth, 676
cocaine abstinence-related dysphoria, reversal by bromocriptine, A1006
cocaine abuse in North America, 296
Drug Development
computational chemistry and models of the interaction of ligands with receptors, 1147
computer-assisted molecular modeling, 1149
drug design with new type of molecular modeling based on stereochemical complementarity to gene structure, 1173
drug development and registration in Japan, 100
mechanism of action of steroid hormones, 1165
Drug Interactions
buspirone and alprazolam, 1104
moricizine and captopril, A1005
nitroglycerine and low molecular weight heparin, A1001
nitroprusside and heparin, A1001
quinidine and nifedipine, 727
rifampicin and bunazosin, A998
Drug Trials
carryover bias in clinical investigations, 799
integrated design for dose comparison trials, 762

E2020
pharmacokinetics in healthy young and elderly subjects, 1086
Echocardiography
during six hours of bedrest at head-down and head-up tilt and during space flight, 535
Editorial (title)
Big Science Little Science: Science in Controversy, 675
Branded Generics, 779
Defining a Journal, 99
The Direction of the ACCP, 199
Industry Under Siege, 295
New FDA Initiatives, 587
Publication Phobias, 487
Regulating Continuing Medical Education, 1
The Tension Builds, 391
Welcome to the Annual Meeting, 903
Education
legal curriculum for clinical pharmacologists, 22
one-month drug analysis laboratory rotation for doctor of pharmacy students, 790
PharmTest, 400
postmarketing surveillance, clinical and regulatory considerations, 1015
postmarketing surveillance within continuum of drug approval process, 904
regulation of continuing education, 1
teaching clinical pharmacology, 311
visual symbolization to teach pharmacological principles of drug addiction to international audiences, 1139
Elderly Patients. See **Geriatric Patients**
Enalapril
effects in hypertensive patients with proteinuria and impaired glucose metabolism, A771
effects on laboratory stress testing blood pressure in essential hypertension, 433
nifedipine versus, in diabetic patients with hypertension and proteinuria, A772
Endocrine System
androgenic steroid use at major medical center, 253
effect of stress on glycemic control in type II diabetes during glyburide and glipizide therapy, 239
enalapril effects in hypertensive patients with proteinuria and impaired glucose metabolism, A771
enalapril versus nifedipine in diabetic patients with hypertension and proteinuria, A772
hypoglycemia and insulin response to continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I in healthy males, 366
Enoxacin
intravenous, oral cimetidine or ranitidine effects on pharmacokinetics of, 53
Epinephrine
effect on defibrillation thresholds, A1008
Erythropoietin
iron management during treatment with recombinant human erythropoietin in chronic renal failure, 1134
Esmolol
hypothermia and sampling site effects on blood concentrations of, 360
Estrogen
bioequivalence of 17β-estradiol hydroxypropyl-β-cyclodextrin complex in postmenopausal women, 1116
diurnal variation in oophorectomized and postmenopausal women, A999
Ethanol
metabolic responses to treadmill running in well-trained men and, 136
Etoposide
pharmacokinetics in children and infants with short-term and continuous infusion, A1007

Famotidine
effects of continuous ranitidine and intermittent famotidine infusions on gastric pH, 1219
pharmacokinetics and dose-response relationship, 636
FCE 22,178
concentration-dependent protein binding of, 933
dose-ranging safety and pharmacokinetics study of, 373
Felodipine
renal effects of nonhypotensive IV dose of, 732
Fenoldopam mesylate
sodium nitroprusside versus, in acute management of severe systemic hypertension, 549
Finasteride
lack of effect on oxidative metabolism of antipyrine, 967
FK366
aldose reductase inhibitory and uricosuric activities in healthy volunteers, 1122
FK506
computer dosing system for individualizing therapy in transplantation and autoimmune disorders, 599
pharmacokinetics in liver transplant recipients after continuous intravenous infusion, 606
pharmacokinetics in patients awaiting renal transplantation, A1000
5-Fluorouracil
clinical cardiotoxicity of, 1060
Furosemide
lisinopril influence on urinary electrolyte excretion after, in healthy subjects, 640

Gastrointestinal System. *See also* **Motion Sickness**
danazol absorption after administration to different sites of gastrointestinal tract and relationship to single- and double-peak phenomena in plasma profiles, 1207
effect of cisapride on esophageal exposure to acid through acceleration of gastric emptying, A1002
effects of continuous ranitidine and intermittent famotidine infusions on gastric pH, 1219
famotidine pharmacokinetics and dose-response relationship, 636
localization of drug release sites from oral sustained-release formulation of 5-ASA in gastrointestinal tract using gamma scintigraphy, 712
paracetamol absorption kinetics as noninvasive measurement of gastric emptying, A1002
ranitidine safety in elderly versus non-elderly patients, 79
twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg, 70
Gemfibrozil
effects on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia, 35
Gentamicin
pharmacokinetics determination by bioelectrical impedance in critically ill adults, 562
Gepirone
effect of food on bioavailability in humans, 631
Geriatric Patients
alpha$_1$-adrenergic blocking agents in, 2
aztreonam pharmacokinetics in healthy elderly and young adult volunteers, 470
ketoprofen pharmacokinetics in elderly, rheumatic disease, renal function, and dose and, 1052
pharmacokinetics of E2020 in healthy young and elderly subjects, 1086
ranitidine safety in elderly versus non-elderly patients, 79
renal protective effect of misoprostol in elderly, osteoarthritis patients at risk for NSAID-induced renal dysfunction, 1225
vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster, 918

Glipizide
effect of stress on glycemic control in type II diabetes during therapy with, 239
Glyburide
effect of stress on glycemic control in type II diabetes during therapy with, 239
Glycerol
iodinated glycerol for treatment of stable chronic bronchitis, 856
Growth Factors
hypoglycemia and insulin response to continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I in healthy males, 366

Health Care Policy
role of research-based pharmaceutical industry in medical progress in the United States, 412
Heart Failure
digoxin pharmacokinetics and perindopril in, 146
ethnic differences on effect on clearance of theophylline, A1004
Heparin
interaction with nitroprusside, A1001
nitroglycerine interaction with low molecular weight heparin, A1001
renin-angiotensin-aldosterone system and prostaglandin role in antihypertensive effect of, 342
resistance caused by intravenous nitroglycerine, A1001
Hepatic Function
antipyrine kinetics in patients with primary biliary cirrhosis, 75
cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949
effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics, 480
effect of pregnancy on hepatic drug metabolism, A1003
first-pass metabolism of problematic drugs, 657
FK506 pharmacokinetics in liver transplant recipients after continuous intravenous infusion, 606
inhibition of ifosfamide metabolism by human and rat liver microsomes, A1008
methylprednisolone hemisuccinate and methylprednisolone pharmacokinetics in chronic liver disease, 805
single-dose pharmacokinetics of cetirizine in chronic liver disease, 929
HMG-CoA Reductase Inhibitors
effects of one year of treatment with pravastatin on lipoprotein a, 574
plasma CoQ10-lowering effect by, 226
H_1-Receptor and H_2-Receptor Antagonists
for acute postoperative pain, 944
pharmacokinetics of orally administered levocabastine in patients with renal insufficiency, 1214
Human Mass Balance/Metabolite Identification Studies
using stable isotope (^{13}C, ^{15}N) labeling and continuous-flow isotope-ratio mass spectrometry as alternative to radioactive labeling methods, A1003, 246
Hydrochlorothiazide
blood pressure assessment during treatment with naproxen or ibuprofen in hypertensive patients treated with, 971
pyrazinoylguanidine versus, in patients with renal insufficiency, 554
Hypertension. See **Antihypertensive Agents**
Hypertriglyceridemia
gemfibrozil effects on fatty acids in lipid fractions of plasma from patients with, 35
Hypotension
autonomic orthostatic hypotension in patients and bedrest subjects, A770
lower body negative pressure to counter symptoms of orthostatic intolerance in patients, bed rest subjects, and astronauts, 1071

Ibuprofen
blood pressure assessment during treatment with, in hypertensive patients treated with hydrochlorothiazide, 971
Ifosfamide
inhibition of metabolism by human and rat liver microsomes, A1008
Immunopharmacology
in children, 316
Immunosuppressive Drugs
azathioprine pharmacokinetics after repeated oral and single intravenous administration, 522
computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders, 599
disposition of olsalazine and metabolites in breast milk, 703
FK506 pharmacokinetics in liver transplant recipients after continuous intravenous infusion, 606
localization of drug release sites from oral sustained-release formulation of 5-ASA in gastrointestinal tract using gamma scintigraphy, 712
pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration, 936
pharmacokinetics of cyclosporine and steady-state aspirin during coadministration, 513
reflectance spectrophotometry in human corticosteroid skin blanching assay, 707
Interleukin-1
effects on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage *in vitro*, 109
Isoproterenol
pharmacokinetics in critically ill pediatric patients, 29
Itraconazole
effect on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201

Keterolac
enhancement of pain control in sickle cell vasoocclusive crisis by, A1009
Ketoconazole
pharmacokinetics after coadministration with didanosine in patients seropositive for human immunodeficiency virus, 912
Ketoprofen
pharmacokinetics in elderly, rheumatic disease, renal function, and dose and, 1052
Kidney. See **Renal Function**

Labetalol
during third trimester of pregnancy, 979
Levocabastine
pharmacokinetics of orally administered levocabastine in patients with renal insufficiency, 1214
Lipid-Lowering Agents
effect of fat content on bioavailability of CI-976, A1000
effects of one year of treatment with pravastatin on lipoprotein a, 574
lack of effect of lovastatin on oral glucose tolerance in hypercholesterolemic patients, 581
plasma CoQ10-lowering effect by HMG-CoA reductase inhibitor, 226
pyrazinoylguanidine effects on glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus, 823
Lisinopril
influence on urinary electrolyte excretion after furosemide in healthy subjects, 640
Liver. See **Hepatic Function**
Lomefloxacin
cefuroxime axetil versus, in acute bacterial exacerbation of chronic bronchitis, A1007
Losartan
slow IV infusion of E-3174 metabolite of, in hypertension, A1003
Lovastatin
lack of effect on oral glucose tolerance in hypercholesterolemic patients, 581
Lung. See **Pulmonary System**

Magnesium Sulfate
effect on action potential duration and cardiac arrhythmias, A1001
Marketing
integrating worldwide marketing needs and clinical research, 989
Metabolism, A1003
of acadesine, 955
clinical implications of first-pass metabolism, 670
effect of pregnancy on hepatic drug metabolism, A1003
effect of stress on glycemic control in type II diabetes during glyburide and glipizide therapy, 239
effects of diltiazem and cimetidine on theophylline oxidative metabolism, 1233
enalapril effects in hypertensive patients with proteinuria and impaired glucose metabolism, A771
fluid balance and thermoregulation with carbohydrate-electrolyte and carbohydrate-electrolyte-glycerol beverages during 14 hours of simulated desert conditions, A771
hepatic first-pass metabolism of problematic drugs, 657
human mass balance/metabolite identification studies using stable isotope (^{13}C, ^{15}N) labeling and continuous-flow isotope-ratio mass spectrometry as alternative to radioactive labeling methods, 246
inhibition of ifosfamide metabolism by human and rat liver microsomes, A1008
lack of effect of finasteride on oxidative metabolism of antipyrine, 967
mechanisms and consequences of presystemic extraction, 650
Metalloproteinases
naproxen and interleukin-1 effects on activity in normal articular cartilage *in vitro*, 109
Methylnaltrexone
dose-related antagonism of emetic effect of morphine by, in dogs, 747
Methylprednisolone
methylprednisolone hemisuccinate and methylprednisolone pharmacokinetics in chronic liver disease, 805
oral methylprednisolone acetate for seasonal rhinitis, 816
Methylscopolamine
effects in young men on steady-state β-blocker treatment, A1003
Metoprolol
comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring, 418
selectivity in healthy volunteers estimated by extent that drugs occupy β_2-receptors in circulating plasma, 959
Migraine
therapeutic advances in, 200
Minoxidil Sulfotransferase
correlation between skin and platelet activity of, A1005
Misoprostol
renal protective effect in elderly, osteoarthritis

patients at risk for NSAID-induced renal dysfunction, 1225
Moricizine
effect on defibrillation thresholds, A1008
pharmacokinetic interaction with captopril in healthy volunteers, A1005
plasma protein binding of, A1005
Morphine
dose-related antagonism of emetic effect by methylnaltrexone in dogs, 747
effects on arterial blood gases in healthy human volunteers, 453
Motion Sickness
effects of motion sickness and antimotion sickness drugs on gastric emptying, A767
effects on central nervous system, A768
etiological significance of arginine vasopressin in, A767
M-5041T
pharmacokinetics and pharmacodynamics in healthy subjects, 1192
influence of application site on, 1188
Musculoskeletal System
diphosphonate and beta agonist attenuating bone and muscle changes induced by simulated microgravity, A771
Myocardial Infarction
partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors, 40

Naproxen
blood pressure assessment during treatment with, in hypertensive patients treated with hydrochlorothiazide, 971
effects on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage *in vitro*, 109
Neuropeptide-Y
protection of ventricle from arrhythmogenic actions of norepinephrine without reducing contractility, A1009
Nicotine
Nicoderm pharmacokinetics in women and obese men compared with normal-sized men, 644
single- and multiple-dose pharmacokinetics of Nicoderm, 161
steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm, 161
Nifedipine
effect of pretreatment periods with diltiazem on kinetics of, 222
effects on pharmacokinetics and dynamics of diltiazem in normal volunteers, 738
enalapril versus, in diabetic patients with hypertension and proteinuria, A772
pharmacokinetic and pharmacodynamic interaction between quinidine and, 727
pharmacokinetics in different populations, 140
Nisoldipine, 46
anti-anginal and anti-ischemic efficacy in chronic stable angina pectoris, A999
Nitroglycerine
interaction with low molecular weight heparin, A1001
intravenous, causing heparin resistance, A1001
Nitroprusside
interaction with heparin, A1001
Nizatidine
hemofiltrability of nizatidine and its metabolites in patients with renal failure, 324
twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg, 70
Norepinephrine
neuropeptide-Y protection of ventricle from arrhythmogenic actions without reducing contractility, A1009
Norfloxacin
effect of milk on in healthy volunteers, 1238

Olsalazine
disposition of olsalazine and metabolites in breast milk, 703
Ondansetron
pharmacodynamics of intravenous and oral ondansetron in systemic lupus erythematosus, A1004
OPC-21268
pharmacokinetics, safety, and pharmacologic effects in humans, 230
Orlistat
dose-response relationship in healthy volunteers, A1002

Paracetamol
absorption kinetics as noninvasive measurement of gastric emptying, A1002
Penicillin
phenobarbital effects on autonomic function and epileptogenic activity induced by hippocampal injection of penicillin in cats, 837
Perindopril
in heart failure, 146
Pharmacodynamics
budesonide after rectal application in healthy volunteers, A1000
cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949
effect of itraconazole on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201
nifedipine effects on pharmacokinetics and dynamics of diltiazem in normal volunteers, 738
pharmacodynamic mediated change in rhM-CSF pharmacokinetics, A1008
pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine, 727
receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids, 115
sematilide in volunteers, A998

twice-a-day diltiazem formulations, A997
Pharmacokinetics
azathioprine after repeated oral and single intravenous administration, 522
aztreonam in healthy elderly and young adult volunteers, 470
beta-methyldigoxin in subjects with normal and impaired renal function, 154
bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotype technique, 89
cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis, 949
clentiazem pharmacokinetics after intravenous and oral administration in healthy subjects, 354
digoxin pharmacokinetics and perindopril in heart failure, 146
effect of fat content on bioavailability of CI-976, A1000
effect of food and monoglyceride emulsion formulation on danazol bioavailability, 381
effect of food on bioavailability of gepirone in humans, 631
effect of itraconazole on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201
effect of milk on absorption of norfloxacin in healthy volunteers, 1238
effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics, 480
effect of time of food administration on bioavailability of didanosine from chewable tablet formulation, 568
effects of concomitantly administered cimetidine or ranitidine on pharmacokinetics of ritanserin, 330
effects of diltiazem and cimetidine on theophylline oxidative metabolism, 1233
etoposide in children and infants with short-term and continuous infusion, A1007
famotidine, 636
of FCE 22,178, 373
FK506 in patients awaiting renal transplantation, A1000
gentamicin pharmacokinetics determination by bioelectrical impedance in critically ill adults, 562
intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis, 475
isoproterenol in critically ill pediatric patients, 29
ketoprofen pharmacokinetics in elderly, rheumatic disease, renal function, and dose and, 1052
methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease, 805
multiple-dose evaluation of codeine sulfate sustained-release tablets, A1006
Nicoderm in women and obese men compared with normal-sized men, 644
nifedipine effects on pharmacokinetics and dynamics of diltiazem in normal volunteers, 738
nifedipine pharmacokinetics in different populations, 140
OPC-21268 in humans, 230
oral cimetidine or ranitidine effects on pharmacokinetics of intravenous enoxacin, 53
orally administered levocabastine in patients with renal insufficiency, 1214
pharmacodynamic mediated change in rhM-CSF pharmacokinetics, A1008
pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine, 727
preclinical studies, A999
prediction of rhM-CSF pharmacokinetics through allometric scaling, A1008
receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids, 115
of RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration, 84
sematilide in volunteers, A998
single- and multiple-dose pharmacokinetics of clarithromycin, 719
single- and multiple-dose pharmacokinetics of Nicoderm, 161
single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers, 439
single-dose administration of tirilazad mesylate, 169
steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm, 161
Sygen pharmacokinetics after single IV administration to healthy volunteers, A997
twice-a-day diltiazem formulations, A997
vigabatrin following single and multiple oral doses in normal volunteers, 458
PharmTest
development of, 400
Phenobarbital
effects on autonomic function and epileptogenic activity induced by hippocampal injection of penicillin in cats, 837
Phenytoin
bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotype technique, 89

as countermeasure for motion sickness in NASA maritime operations, A767
Pravastatin
effects of one year of treatment on lipoprotein a, 574
Pregnancy
effect on hepatic drug metabolism, A1003
labetalol during third trimester of, 979
Promethazine
failure of promethazine to cause sedation during space flight, A772
Propranolol
chronopharmacokinetic profile in hypertensive subjects, 756
Prostacyclin
relationship between degradation of prostacyclin in blood and antiplatelet drug effects in, 1048
Prostaglandins
role in antihypertensive effect of heparin, 342
Proteinuria
enalapril versus nifedipine in diabetic patients with hypertension and proteinuria, A772
Proteoglycans
naproxen and interleukin-1 effects on catabolism in normal articular cartilage *in vitro*, 109
Psychopharmacotherapy
on long-duration space missions, A771
Pulmonary System
iodinated glycerol for treatment of stable chronic bronchitis, 856
lomefloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis, A1007
theophylline steady-state pharmacokinetics in COPD patients treated with dirithromycin, 861
Pyrazinoylguanidine
hydrochlorothiazide versus, in patients with renal insufficiency, 554

Quinidine
pharmacokinetic and pharmacodynamic interaction between nifedipine and, 727

Ranitidine
effects of continuous ranitidine and intermittent famotidine infusions on gastric pH, 1219
effects on pharmacokinetics of ritanserin, 330
oral, effects on pharmacokinetics of intravenous enoxacin, 53
safety in elderly versus non-elderly patients, 79
twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg, 70
Regulation
drug development and registration in Japan, 100
postmarketing surveillance, clinical and regulatory considerations, 1015
regulatory and review process in Guyana, 14
Renal Function
beta-methyldigoxin pharmacokinetics in subjects with normal and impaired renal function, 154
blood pressure control, hematocrit level, and renal function in treated essential hypertension, 427
FK506 pharmacokinetics in patients awaiting renal transplantation, A1000
hemofiltrability of nizatidine and its metabolites in patients with renal failure, 324
impact of clinical pharmacological/renal dosing service at large teaching hospital, A1007
impaired elimination of atenolol in nephropathic patient with self-medication overdose, 450
iron management during treatment with recombinant human erythropoietin in chronic renal failure, 1134
nonhypotensive IV dose of felodipine, 732
pharmacokinetics and dialyzability of sulindac and metabolites in end-stage renal failure, 527
pharmacokinetics of orally administered levocabastine in patients with renal insufficiency, 1214
pyrazinoylguanidine versus hydrochlorothiazide in patients with renal insufficiency, 554
renal effects of antihypertensive medications, 392
renal protective effect of misoprostol in elderly, osteoarthritis patients at risk for NSAID-induced renal dysfunction, 1225
selective alpha-1 adrenoreceptor blockade and renal sodium handling in humans, 1110
Renin-Angiotensin-Aldosterone System
partial escape of blockade in patients with acute myocardial infarction treated with ACE inhibitors, 40
role in antihypertensive effect of heparin, 342
Research
integrating worldwide marketing needs and clinical research, 989
Rhinitis
oral methylprednisolone acetate for seasonal rhinitis, 816
rhM-CSF
pharmacodynamic mediated change in rhM-CSF pharmacokinetics, A1008
prediction of pharmacokinetics through allometric scaling, A1008
Rifampicin
interaction with bunazosin, A998
Ritanserin
effects of concomitantly administered cimetidine or ranitidine on pharmacokinetics of, 330
Ro 23-9424
in vitro activity of, 923

Scopolamine
facilitation of adaptation and acute tolerance to stressful sensory input by, 1092
Secobarbital
effects on arterial blood gases in healthy human volunteers, 453
Sematilide
pharmacokinetic/pharmacodynamic modeling in volunteers, A998
Serotonin
participation on early and delayed emesis induced by cisplatinum-based chemotherapy, 691
Sickle Cell Disease
codeine disposition in sickle cell patients compared with healthy volunteers, 811
enhancement of pain control in sickle cell vasoocclusive crisis by intravenous keterolac, A1009
Sodium Nitroprusside
fenoldopam mesylate versus, in acute management of severe systemic hypertension, 549
Sotalol
review of, 508
Space Flight
diphosphonate and beta agonist attenuating bone and muscle changes induced by simulated microgravity, A771
early stopping of aerospace medical trial, application of sequential principles to, A773
echocardiograms during six hours of bedrest at head-down and head-up tilt and during space flight, 535
effect of anti-G suit inflation on cardiac volumes determined by two-dimensional echocardiography during +Gz acceleration, A768
failure of promethazine to cause sedation during, A772
Guyton model analysis of physiologic response to preadaptation of blood volume as countermeasure to fluid shifts, A768
interaction between hypoxia and simulated microgravity, A773
lower body negative pressure to counter symptoms of orthostatic intolerance in patients, bed rest subjects, and astronauts, 1071
phenytoin as countermeasure for motion sickness in NASA maritime operations, A767
physiologically-based pharmacokinetic model of acetaminophen for application in analysis of space flight data, A770
psychopharmacotherapy on long-duration missions, A771
responses to acute and repetitive hyper- and hypogravity produced by parabolic flight, A769
space sickness and fluid shifts, A768
surgical problems in space, A773
syncope and, A770
Spirapril
effects on renal hypertension in patients with essential hypertension, 348
Steroid Hormones
mechanism of action of, 1165
Stress
autogenic feedback training improvement of pilot performance during high stress conditions, A773
effect on glycemic control in type II diabetes during glyburide and glipizide therapy, 239
facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine, 1092
influence of prenatal and neonatal stress on reproduction in hamsters, A774
Succinylcholine
hyperkalemia to, d-tubocurarine infusion with and without immobilization causing, A1007
Sulindac
pharmacokinetics and dialyzability of sulindac and metabolites in end-stage renal failure, 527
Sygen
pharmacokinetics after single IV administration to healthy volunteers, A997
Syncope
spectrum of, A770
Systemic Lupus Erythematosus
pharmacodynamics of intravenous and oral ondansetron in, A1004

Terazosin
alpha$_1$-receptor blockade with terazosin, 866
effects on laboratory stress testing blood pressure in essential hypertension, 433
long-term efficacy and safety, 272
Terfenadine
effect of itraconazole on single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, 1201
Tetracaine
ultra-long duration local anesthesia with lecithin-coated tetracaine microcrystals, A772
Theophylline
effects of diltiazem and cimetidine on oxidative metabolism of, 1233
ethnic differences on effect of heart failure on clearance of, A1004
steady-state pharmacokinetics in COPD patients treated with dirithromycin, 861
Therapeutic Reviews
alpha$_1$-adrenergic blocking agents in geriatric patients, 2
angiotensin II receptor blockade, 1023
cocaine abuse in North America, 296
iron management during treatment with recombinant human erythropoietin in chronic renal failure, 1134
nitric oxide, 488
renal effects of antihypertensive medications, 392
therapeutic advances in migraine, 200

Thromboxane Synthase Inhibitors
concentration-dependent protein binding of FCE 22,178, 933

Timolol
beta-adrenergic blocking properties of S- and R-timolol in humans, 544

Tirilazad Mesylate
pharmacokinetics and tolerability of single-dose administration of, 169

Toleration
single-dose administration of tirilazad mesylate, 169

Toxins
intramuscular antidotes for cyanide poisoning, A997
pediatric gastrointestinal decontamination in acute toxin ingestion, 497
poisonous land and sea snakes found in and around Saudi Arabia, A774

Trandolapril
once-daily compared with twice-daily formulation in mild to moderate essential hypertension, 832

Transplantation
computer dosing system for individualizing FK506 therapy in, 599
FK506 pharmacokinetics in liver transplant recipients after continuous intravenous infusion, 606
FK506 pharmacokinetics in patients awaiting renal transplantation, A1000

d-Tubocurarine
infusion with and without immobilization, hyperkalemia to succinylcholine caused by, A1007

Valproic Acid
effects of unbound clearance on binding parameters to serum proteins, 130

Vancomycin
pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster, 918

Ventricular Tachycardia
efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs, 623

Verapamil
in hypertensive rats on high-calcium diet, 335

Vigabatrin
pharmacokinetics following single and multiple oral doses in normal volunteers, 458

Warfarin
free warfarin extraction methods, A1005